

RESPONDER-HF

A confirmatory trial of the Corvia® Atrial Shunt for heart failure patients with an EF $\geq 40\%$



WHAT IS RESPONDER-HF?

A randomized, double-blinded, sham-controlled trial to confirm the clinical efficacy of the Corvia Atrial Shunt in HF patients with an LVEF $\geq 40\%$, elevated left sided filling pressures, and who remain symptomatic despite Guideline Directed Medical Therapy (GDMT).

STUDY RATIONALE

To confirm the findings from REDUCE LAP-HF II, the largest randomized controlled trial of a device-based therapy for HFpEF. Results from REDUCE LAP-HF II showed that in the large responder population, representing 50% of patients, treatment with the Corvia Atrial Shunt resulted in a 45% reduction in HF events ($p=0.034$) and a 55% greater improvement in quality of life compared to sham control at one year ($p=0.027$).¹

TRIAL DESIGN

The study closely mirrors REDUCE LAP-HF II, with new exclusions for patients with worse right ventricular function resulting from latent pulmonary vascular disease (identified by elevated exercise PVR) or associated with cardiac rhythm devices.

STUDY POPULATION

N = 260 randomized

- + Age ≥ 40
- + Preserved RV function
- + Exercise PCWP (≥ 25 mmHg) with left-to-right gradient (≥ 5 mmHg)
- + Exercise PVR < 1.75 WU
- + No cardiac rhythm device



CORVIA ATRIAL SHUNT

N = 130

SHAM CONTROL

N = 130

PRIMARY COMPOSITE ENDPOINT

- + Rate of total HF events (first and recurrent) up to 24 months, analyzed when last randomized patient reaches 12 months
- + KCCQ (OSS) change from baseline to 12 months

MAJOR SECONDARY ENDPOINT

- + Cardiovascular mortality through 12 months

WHO SHOULD BE CONSIDERED?

Patients age 40+ who have symptomatic HF or unexplained exertional dyspnea.

- Left ventricular ejection fraction $\geq 40\%$
- New York Heart Association class II–IV
- Relatively normal right ventricular function
- Elevated left-sided filling pressures
- Absence of significant valve disease
- Absence of a cardiac rhythm device

¹ Borlaug, BA et al.. *Circulation*. 2022;10.1161.

Study sponsored by Corvia Medical. clinicaltrials.gov/identification/NCT05425459

Corvia Medical Australia Pty Ltd
Level 61 - 1 Farrer Place
Sydney NSW 2000 AUS

Corvia Medical, Inc.
One Highwood Drive, Suite 300
Tewksbury, MA 01876 USA

Corvia and IASD are registered trademarks of Corvia Medical, Inc.
©2023 Corvia Medical, Inc. All rights reserved.
PS00743, 00732AW Rev00 2023-02



Learn more

Consider giving your
HFpEF patients a new
opportunity to find relief.



CAUTION: Investigational Device.
Limited by United States law to investigational use.

The **Corvia Atrial Shunt System** is an **Investigational Device**,
exclusively for use in a Clinical Investigation.